1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow MPS VII: new trials by email Literature Review of MPS VII trials Research Report on MPS VII
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age UX003 - Sly Syndrome, MPS VII | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 8 | 2015-07-21 | 2019-10-30 |
Lysosomal Storage Diseases (1) · Metabolic Diseases (1) · Mucopolysaccharidoses (1) · Mucopolysaccharidosis VII (1) · Rare Diseases (1)
Carbohydrate Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Metabolism, Inborn Errors (1) · Mucinoses (1) · Nutritional and Metabolic Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Skin and Connective Tissue Diseases (1)
Ultragenyx Pharmaceutical Inc (1)
Portugal (1) · Spain (1) · United States (1)
PMID 30467742, PMID 35331634, PMID 37415957
2015 (1)